白细胞介素 6在银屑病发病中作用的研究进展

doi:10.3969/j.issn.1674-490X.2016.05.010

医学研究与教育 ›› 2016, Vol. 33 ›› Issue (5): 44-48.DOI: 10.3969/j.issn.1674-490X.2016.05.010

白细胞介素 6在银屑病发病中作用的研究进展

孙海严,丁秋允,史义军,楚瑞琦

河北大学附属医院, 河北保定 071000

收稿日期:2016-03-24 出版日期:2016-10-25 发布日期:2016-10-25
通讯作者: 楚瑞琦(1968—),男,河北保定人,教授,博士,硕士生导师,主要从事银屑病及发病机理研究。E-mail: churuiqi1968@163.com
作者简介:孙海严(1990—),女,河北邢台人,在读硕士。

Advances on the role of interleukin-6 in the pathogenesis of psoriasis

SUN Haiyan,DING Qiuyun,SHI Yijun,CHU Ruiqi

Affiliated Hospital of Hebei University, Baoding 071000, China)Abstract:

Received:2016-03-24 Online:2016-10-25 Published:2016-10-25

摘要/Abstract

摘要： 银屑病是一种慢性炎症性增生性皮肤病,其发病原因复杂,多认为与免疫因素相关。在银屑病中,白细胞介素6(interleukin-6,IL-6)诱导角质形成细胞的分化和增殖、参与T细胞的活化、促进角质形成细胞产生血管内皮生长因子、白细胞介素8(interleukin-8,IL-8)等细胞因子,促进皮损形成,IL-6还与银屑病合并骨质疏松、高脂血症、心血管疾病的发生有关。

关键词: 银屑病, 白细胞介素6, T细胞, 角质形成细胞

Abstract: Psoriasis is a chronic inflammatory skin disease characterized by increased epidermal thickness.The causes of the disease are complex,many people believe it is an autoimmune-related skin disease.The course of the disease is long,and the recurrent attacks of the disease are easy.Interleukin 6(IL-6)can induct differentiation and proliferation of keratinocytes and induce the activation of T cells,stimulate keratinocytes to produce cytokines including vascular endothelial growth factor(VEGF),IL-8,these cytokines may play important roles in the development or aggravation of psoriasis,IL-6 is also related to psoriasis-caused osteoporosis,hyperlipidemia,and cardiovascular diseases.

Key words: psoriasis, interleukin-6, T cell, keratinocyte

中图分类号:

孙海严,丁秋允,史义军,楚瑞琦. 白细胞介素 6在银屑病发病中作用的研究进展[J]. 医学研究与教育, 2016, 33(5): 44-48.

SUN Haiyan,DING Qiuyun,SHI Yijun,CHU Ruiqi. Advances on the role of interleukin-6 in the pathogenesis of psoriasis[J]. Medical Reserch and Education, 2016, 33(5): 44-48.

参考文献

[1] LEE S Y,BUHIMSCHI I A,DULAY A T,et al.IL-6 trans-signaling system in intra-amniotic inflammation,preterm birth,and preterm birth and preterm premature rupture of the membranes[J].J Immunol,2011,186(5):3226-3236.DOI:10.4049/jimmunol.1003587.
[2] ANDREA S,SERGIO C,ANDREA C.IL-6 as a druggable target in psoriasis:focus on pustular variants[J].Journal of Immunology Research,2014,964069:1-10.DOI:10.1155/2014/964069.
[3] SCHELLER J,CHALARIS A,SCHMIDT-ARRAS D,et al.The pro- and anti-inflammatory properties of the cytokine interleukin-6[J].Biochim Biophys Acta,2011,1813(5):878-888.DOI:10.1016/j.bbamcr.2011.01.034.
[4] DAYER J M,CHOY E.Therapeutic targets in rheumatoid arthritis:the interleukin-6 receptor[J].Rheumatology(oxford),2010,49(1):15-24.DOI:10.1093/rheumatology/kep329.
[5] LOWES M A,SUAREZ-FARINAS M,KRUEGER J G.Immunology of psoriasis[J].Annu Rev Immunol,2014,32:227-255.DOI:10.1146/annurev-immunol-032713-120225.
[6] TAKAHASHI H,TSUJI H,HASHIMOTO Y.Serum cytokines and growth factor levels in Japanese patients with psoriasis[J].Clinical and Experimental Dermatology,2010,35(6):645-649.DOI:10.1111/j.1365-2230.2009.03704.
[7] FUJISHIMA S,WATANABE H,KAWAGUCHI M,et al.Involvement of IL-17F via the induction of IL-6 in psoriasis[J].Arch Dermatol Res,2010,302(7):499-505.DOI:10.1007/s00403-010-1033-8.
[8] CROXFORD A L,KARBACH S,KURSCHUS F C.IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions[J].J Invest Dermatol,2014,134(3):728-735.DOI:10.1038/jid.2013.404.
[9] NIEDBALA W,ALVES-FILHO J C,FUKADA S Y,et al.Regulation of type 17 helper T-cell function by nitric oxide during inflammation[J].Proc Natl Acad Sci USA,2011,108(22):9220-9225.DOI:10.1073/pnas.1100667108.
[10] ATAIE-KACHOIE P,POURGHOLAMI M H,MORRIS D L.Inhibition of the IL-6 signaling pathway:a strategy to combat chronic inflammatory diseases and cancer[J].Cytokine and Growth Factor,2013,24(2):163-173.DOI:10.1016/j.cytogfr.2012.09.001.
[11] LUTING Y,BING L,DANG E,et al.Impaired function of regulatory T cells in patients with is mediated by phosphorylation of STAT3[J].J Dermatol Sci,2016,81(2):85-92.DOI:10.1016/j.jdermsci.2015.11.007.
[12] MABUCHI T,CHANG T W,QUINTER S,et al.Chemokine receptors in the pathogenesis and therapy of psoriasis[J].J Dermatol Sci,2012,65(1):4-11.DOI:10.1016/j.jdermsci.2011.11.007.
[13] SCHON M P,RUZICKA T.Psoriasis:the plot thickens[J].Nat Immunol,2001,2(2):91.
[14] VERKHRATSKY A,BURNSTOCK G.Biology of purinergic signalling:its ancient evolutionary roots,its omnipresence and its multiple functional significance[J].Bioessays,2014,36(7):697-705.DOI:10.1002/bies.201400024.
[15] ISHIMARU M,TSUKIMOTO M,HARADA H,et al.Involvement of P2Y11 receptor in IFN-γ-induced IL-6 production in human keratinocytes[J].Eur J Pharmacol,2013,703(1-3):67-73.DOI:10.1016/j.ejphar.2013.02.020.
[16] FLISIAK I,ZANIEWSKI P,ROGALSKA M,et al.Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales[J].Cytokine,2013,61(2):690.DOI:10.1016/j.cyto.2012.11.012.
[17] CANAVESE M,ALTRUDA F,RUZICKA T,et al.Vascular endothelial growth factor(VEGF)in the pathogenesis of psoriasis-A possible target for novel therapier?[J].J Dermatol Sci,2010,58(3):171-176.DOI:10.1016/j.jdermsci.2010.03.023.
[18] ELIAS P M,ARBISER J,BROWN B E,et al.Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis,dermal angiogenesis and the development of epidermal hyperplasis: implications for the pathogenesis of psoriasis[J].Am J Pathol,2008,173(3):689-699.DOI:10.2353/ajpath.2008.080088.
[19] BALTA I,BALTA S,DEMIRKOL S,et al.Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris[J].Angiology,2014,65(1):74-78.DOI:10.1177/0003319713485805.
[20] TORRES T,SELORES M.Does treatment of metabolic syndrome components improve psoriasis?Report of three cases[J].Eur J Dermatol,2012,22(2):270-272.DOI:10.1684/ejd.2011.1614.
[21] QADIM H H,GOFOROUSHAN F,NEJAD S B,et al.Study the calcium serum level in patients suffering from psoriasis[J].Pak J Biol Sci,2013,16(6):291-294.
[22] SCHAFER J A,KJESBO N K,GLEASON P P.Formulary review of 2 new biologic agents:tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis[J].J Manag Care Pharm,2010,16(6):402-416.
[23] TOSHIO T,TADAMITSU K.Targeting interleukin-6:all the way to treat autoimmune and inflammatory diseases[J].Inter J Biological Sci,2012,8(9):1227-1236.DOI:10.7150/ijbs.4666.

白细胞介素 6在银屑病发病中作用的研究进展

Advances on the role of interleukin-6 in the pathogenesis of psoriasis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

[1]	刘慧芳,高翔,赵会娟,陈胜德,孟明. 3种品系小鼠iNKT细胞组织特异性分布[J]. 医学研究与教育, 2018, 35(6): 10-18.
[2]	王园园,叶闽,张静雯,崔卓,李子琦,刘慧芳,孟明. α-Galcer尾根皮下注射对小鼠体内不同器官中iNKT细胞频率及亚群的影响[J]. 医学研究与教育, 2018, 35(2): 17-25.
[3]	赵会娟,尹晓琳,王园园,刘慧芳,孟明,陈冬志. iNKT细胞在肥胖脂肪组织慢性炎症发生中的作用[J]. 医学研究与教育, 2018, 35(1): 19-24.
[4]	刘绍川,娄永富,胡鸿鹏,杨飞,孟明. T1D发病中的双刃剑——iNKT细胞[J]. 医学研究与教育, 2016, 33(4): 47-51.
[5]	段斐,郝华超,薛娟,李少春,刘未华,谷雨,孙晓芳. α-玉米赤霉醇对大鼠成骨细胞IL-6表达及分泌的影响[J]. 医学研究与教育, 2014, 31(1): 1-7.
[6]	冯娜,王晓曼,王梦,任亚莉,马宁,曹志然. 布鲁菌S2感染后死亡的巨噬细胞启动T细胞应答的作用[J]. 医学研究与教育, 2013, 30(6): 1-4,34.
[7]	赵杏苗,马光,韩莉,李会芹,安毅. 中药浴联合阿维A治疗寻常型银屑病疗效观察[J]. 医学研究与教育, 2010, 27(3): 66-67.
[8]	赵建伟,刘春梅,赵桂香,张红岩. 阿维A治疗脓疱型银屑病疗效观察[J]. 医学研究与教育, 2009, 26(2): 41-42.